Provided by Tiger Fintech (Singapore) Pte. Ltd.

crane

190.00
-1.9900-1.04%
Volume:405.03K
Turnover:77.03M
Market Cap:10.93B
PE:31.58
High:192.17
Open:191.00
Low:189.20
Close:191.99
52wk High:203.89
52wk Low:127.04
Shares:57.55M
Float Shares:48.77M
Volume Ratio:1.48
T/O Rate:0.83%
Dividend:0.87
Dividend Rate:0.46%
EPS(TTM):6.02
EPS(LYR):5.15
ROE:17.94%
ROA:9.25%
PB:5.80
PE(LYR):36.88

Loading ...

Crane Is Maintained at Buy by B of A Securities

Dow Jones
·
39 mins ago

When Should You Buy Crane Company (NYSE:CR)?

Simply Wall St.
·
Yesterday

Ascentage Pharma Announces Global Registrational Phase III Study of Lisaftoclax for First-line Treatment of Patients with Higher-Risk Myelodysplastic Syndrome Cleared by US FDA and EMA

GlobeNewswire
·
Aug 18

Protara Beats Q2 Loss Estimates

Motley Fool
·
Aug 11

CG Oncology Reports Second Quarter 2025 Financial Results and Provides Business Updates

GlobeNewswire
·
Aug 08

Kura Oncology Reports Second Quarter 2025 Financial Results

GlobeNewswire
·
Aug 08

Relmada Therapeutics Reports Second Quarter 2025 Financial Results and Announces NDV-01 6-Month Follow-up Safety and Efficacy Data in NMIBC

GlobeNewswire
·
Aug 08

UroGen Pharma Expands Commercial Portfolio with Launch of ZUSDURI™ and Reports Second Quarter 2025 Financial Results

GlobeNewswire
·
Aug 07

Host Hotels & Resorts Publishes 2025 Corporate Responsibility Report

GlobeNewswire
·
Aug 06

UroGen Announces 24-Month Duration of Response of 72.2% from the Pivotal Phase 3 ENVISION Trial of ZUSDURI, the First and Only FDA-Approved Medicine for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

GlobeNewswire
·
Aug 05

Syndax Reports Second Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire
·
Aug 05

CERo Therapeutics Doses Second Acute Myeloid Leukemia Patient with CER-1236

GlobeNewswire
·
Jul 31

UBS Adjusts Price Target on Crane to $230 From $215, Maintains Buy Rating

MT Newswires Live
·
Jul 30

Crane Co : UBS Raises Target Price to $230 From $215

THOMSON REUTERS
·
Jul 30

U.S. RESEARCH ROUNDUP-Penumbra, UnitedHealth, Visa

Reuters
·
Jul 30

Crane Co : Stifel Raises Target Price to $200 From $189

THOMSON REUTERS
·
Jul 30

Cardiff Oncology Announces Positive Data from Ongoing Randomized Phase 2 First-line RAS-mutated mCRC Clinical Trial (CRDF-004)

GlobeNewswire
·
Jul 30

Stock Track | Crane Company Soars 5.80% as Multiple Analysts Maintain Positive Ratings

Stock Track
·
Jul 29

Crane Company (CR) Receives a Rating Update from a Top Analyst

TIPRANKS
·
Jul 29

D.A. Davidson Sticks to Their Buy Rating for Crane Company (CR)

TIPRANKS
·
Jul 29